Cargando…

Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis

Upon sunitinib treatment of metastatic renal cell carcinoma patients eventually acquire resistance. Our aim was to investigate microRNAs behind sunitinib resistance. We developed an in vivo xenograft and an in vitro model and compared morphological, immunhistochemical, transcriptomical and miRNome d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butz, Henriett, Ding, Qiang, Nofech-Mozes, Roy, Lichner, Zsuzsanna, Ni, Heyu, Yousef, George M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797004/ https://www.ncbi.nlm.nih.gov/pubmed/29435133 http://dx.doi.org/10.18632/oncotarget.23163

Ejemplares similares

miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1
por: Butz, Henriett, et al.
Publicado: (2015)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

A Cluster-then-label Semi-supervised Learning Approach for Pathology Image Classification
por: Peikari, Mohammad, et al.
Publicado: (2018)

MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal
por: Plotkin, Anna, et al.
Publicado: (2023)

Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy
por: Saleeb, Rola M., et al.
Publicado: (2018)

Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function
por: Prud'homme, Gerald J., et al.
Publicado: (2016)

MicroRNA‐194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma
por: Nofech‐Mozes, Roy, et al.
Publicado: (2016)

miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties
por: Lichner, Zsuzsanna, et al.
Publicado: (2014)

61. EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASIS
por: Qazi, Maleeha, et al.
Publicado: (2020)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer
por: Helpman, L, et al.
Publicado: (2014)

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
por: Hahn, Ezra, et al.
Publicado: (2023)

Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes
por: Butz, Henriett, et al.
Publicado: (2021)

Pan-cancer classification of single cells in the tumour microenvironment
por: Nofech-Mozes, Ido, et al.
Publicado: (2023)

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
por: Maráz, Anikó, et al.
Publicado: (2018)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment
por: Song, Ik Chan, et al.
Publicado: (2009)

Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
por: Kamli, Hossam, et al.
Publicado: (2018)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

Circulating Noncoding RNAs in Pituitary Neuroendocrine Tumors—Two Sides of the Same Coin
por: Butz, Henriett
Publicado: (2022)

MRTF: Basic Biology and Role in Kidney Disease
por: Miranda, Maria Zena, et al.
Publicado: (2021)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Retroperitoneal Extraovarian Fibrothecoma Mimicking a Malignant Epithelial Ovarian Carcinoma
por: Roberts, Patrick, et al.
Publicado: (2012)

EMT in Breast Carcinoma—A Review
por: Felipe Lima, Joema, et al.
Publicado: (2016)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2(+):ERα(-) breast cancer
por: Liu, Jeffrey C., et al.
Publicado: (2017)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib
por: Chen, Ying-Shou, et al.
Publicado: (2009)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
por: Witte, Jeannine, et al.
Publicado: (2018)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fhfbngik0e9p60a9p9h3q09ofo